Guardant Health, Inc. (GH) stock
GHNasdaqServices-Medical LaboratoriesFiscal year ends December 31
$151.70−3.16 (-2.04%)
Close on Nov 13, 2026Market cap $20.36BP/E –Yield –
Guardant Health r&d expenses
Research and development expenses are spending on new products and technology.
Guardant Health's R&D Expenses for the twelve months ending Sep 30, 2026 was $386.67M, up 7.6% year over year. For fiscal 2025 it was $364.19M, up 4.7% from the year before. The highest annual figure on record is $373.81M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $364.19M | +4.7% |
| FY2024 | Dec 31, 2024 | $347.75M | -5.3% |
| FY2023 | Dec 31, 2023 | $367.19M | -1.8% |
| FY2022 | Dec 31, 2022 | $373.81M | +42.0% |
| FY2021 | Dec 31, 2021 | $263.22M | +75.6% |
| FY2020 | Dec 31, 2020 | $149.86M | +73.7% |
| FY2019 | Dec 31, 2019 | $86.29M | +70.2% |
| FY2018 | Dec 31, 2018 | $50.71M | +98.4% |
| FY2017 | Dec 31, 2017 | $25.56M | +135.4% |
| FY2016 | Dec 31, 2016 | $10.86M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $100.84M | +12.1% |
| Q2 FY2026 | Jun 30, 2026 | $96.53M | +10.4% |
| Q1 FY2026 | Mar 31, 2026 | $91.04M | +2.8% |
| Q4 FY2025 | Dec 31, 2025 | $98.26M | +5.0% |
| Q3 FY2025 | Sep 30, 2025 | $89.96M | +3.0% |
| Q2 FY2025 | Jun 30, 2025 | $87.45M | +5.2% |
| Q1 FY2025 | Mar 31, 2025 | $88.52M | +5.6% |
| Q4 FY2024 | Dec 31, 2024 | $93.54M | +4.1% |
| Q3 FY2024 | Sep 30, 2024 | $87.31M | -7.0% |
| Q2 FY2024 | Jun 30, 2024 | $83.10M | -8.0% |
| Q1 FY2024 | Mar 31, 2024 | $83.80M | -10.0% |
| Q4 FY2023 | Dec 31, 2023 | $89.86M | -15.7% |
| Q3 FY2023 | Sep 30, 2023 | $93.85M | -6.2% |
| Q2 FY2023 | Jun 30, 2023 | $90.36M | +5.7% |
| Q1 FY2023 | Mar 31, 2023 | $93.13M | +13.9% |
| Q4 FY2022 | Dec 31, 2022 | $106.58M | +46.0% |
| Q3 FY2022 | Sep 30, 2022 | $100.02M | +40.9% |
| Q2 FY2022 | Jun 30, 2022 | $85.46M | +34.1% |
| Q1 FY2022 | Mar 31, 2022 | $81.76M | +47.3% |
| Q4 FY2021 | Dec 31, 2021 | $73.02M | +81.3% |
| Q3 FY2021 | Sep 30, 2021 | $70.97M | +95.8% |
| Q2 FY2021 | Jun 30, 2021 | $63.72M | +75.5% |
| Q1 FY2021 | Mar 31, 2021 | $55.51M | +50.0% |
| Q4 FY2020 | Dec 31, 2020 | $40.28M | +55.7% |
| Q3 FY2020 | Sep 30, 2020 | $36.25M | +47.5% |
| Q2 FY2020 | Jun 30, 2020 | $36.32M | +85.9% |
| Q1 FY2020 | Mar 31, 2020 | $37.02M | +126.9% |
| Q4 FY2019 | Dec 31, 2019 | $25.88M | +55.4% |
| Q3 FY2019 | Sep 30, 2019 | $24.57M | +72.4% |
| Q2 FY2019 | Jun 30, 2019 | $19.53M | +69.0% |
| Q1 FY2019 | Mar 31, 2019 | $16.32M | +97.6% |
| Q4 FY2018 | Dec 31, 2018 | $16.65M | +105.1% |
| Q3 FY2018 | Sep 30, 2018 | $14.25M | +96.7% |
| Q2 FY2018 | Jun 30, 2018 | $11.55M | – |
| Q1 FY2018 | Mar 31, 2018 | $8.26M | – |
| Q4 FY2017 | Dec 31, 2017 | $8.12M | – |
| Q3 FY2017 | Sep 30, 2017 | $7.25M | – |
See a number that looks wrong?